NO20031232L - Pyridazinoner og triazinoner og medisinsk anvendelse derav - Google Patents

Pyridazinoner og triazinoner og medisinsk anvendelse derav

Info

Publication number
NO20031232L
NO20031232L NO20031232A NO20031232A NO20031232L NO 20031232 L NO20031232 L NO 20031232L NO 20031232 A NO20031232 A NO 20031232A NO 20031232 A NO20031232 A NO 20031232A NO 20031232 L NO20031232 L NO 20031232L
Authority
NO
Norway
Prior art keywords
optionally substituted
group
independent
atom
membered
Prior art date
Application number
NO20031232A
Other languages
English (en)
Other versions
NO327813B1 (no
NO20031232D0 (no
Inventor
Satoshi Nagato
Koki Kawano
Koichi Ito
Yoshihiko Norimine
Kohshi Ueno
Takahisa Hanada
Hiroyuki Amino
Makoto Ogo
Shinji Hatakeyama
Masataka Ueno
Anthony John Groom
Leanne Rivers
Terence Smith
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0102824A external-priority patent/GB0102824D0/en
Priority claimed from GB0102822A external-priority patent/GB0102822D0/en
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of NO20031232D0 publication Critical patent/NO20031232D0/no
Publication of NO20031232L publication Critical patent/NO20031232L/no
Publication of NO327813B1 publication Critical patent/NO327813B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20031232A 2000-09-18 2003-03-17 Pyridazinoner og triazinoner og deres anvendelse, samt farmasoytisk preparat NO327813B1 (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2000282636 2000-09-18
JP2000289412 2000-09-22
JP2000342614 2000-11-09
GB0102824A GB0102824D0 (en) 2001-02-05 2001-02-05 Triazinone compounds process for producing the same and pharmaceuticals thereof
GB0102822A GB0102822D0 (en) 2001-02-05 2001-02-05 Pyridazinone compounds manufacturing methods thereof and pharmaceuticals thereof
PCT/JP2001/008058 WO2002022587A1 (en) 2000-09-18 2001-09-17 Pyridazinones and triazinones and medicinal use thereof

Publications (3)

Publication Number Publication Date
NO20031232D0 NO20031232D0 (no) 2003-03-17
NO20031232L true NO20031232L (no) 2003-05-19
NO327813B1 NO327813B1 (no) 2009-09-28

Family

ID=27516005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031232A NO327813B1 (no) 2000-09-18 2003-03-17 Pyridazinoner og triazinoner og deres anvendelse, samt farmasoytisk preparat

Country Status (16)

Country Link
US (2) US20030225081A1 (no)
EP (1) EP1319659B1 (no)
JP (2) JP4233868B2 (no)
KR (1) KR100770327B1 (no)
CN (1) CN100473647C (no)
AT (1) ATE425148T1 (no)
AU (2) AU2001290229B2 (no)
CA (2) CA2742411A1 (no)
DE (1) DE60137948D1 (no)
HU (1) HU228961B1 (no)
IL (2) IL154709A0 (no)
MX (1) MXPA03002324A (no)
NO (1) NO327813B1 (no)
NZ (1) NZ524745A (no)
TW (1) TWI262915B (no)
WO (1) WO2002022587A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002332286B2 (en) * 2001-09-26 2007-10-18 Kowa Co., Ltd Water-soluble phenylpyridazine derivatives and medicines containing the same
US6861428B2 (en) * 2001-09-26 2005-03-01 Kowa Co., Ltd. Water-soluble phenylpyridazine compounds and compositions containing the same
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
US7462613B2 (en) 2002-11-19 2008-12-09 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7309701B2 (en) 2002-11-19 2007-12-18 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ATE511843T1 (de) * 2005-04-04 2011-06-15 Eisai R&D Man Co Ltd Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
EP1953147A1 (en) * 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
WO2007066601A1 (ja) 2005-12-07 2007-06-14 Sumitomo Chemical Company, Limited ピリダジン化合物及びその用途
EP2127653A1 (en) * 2007-01-29 2009-12-02 Kowa Co., Ltd. Agent for treatment of multiple sclerosis
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
US20100130537A1 (en) * 2007-04-26 2010-05-27 Eisai R&D Management Co., Ltd Cinnamide compounds for dementia
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014117919A1 (en) * 2013-02-04 2014-08-07 Merck Patent Gmbh Positive allosteric modulators of mglur3
US8877766B2 (en) * 2013-02-15 2014-11-04 Peter F. Kador Neuroprotective multifunctional antioxidants and their monofunctional analogs
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
WO2016051799A1 (ja) * 2014-10-01 2016-04-07 学校法人同志社 ２－アミノヒドロキノン誘導体及びタウ凝集阻害剤
CN111153859B (zh) * 2015-04-15 2021-09-03 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
CN108349989B (zh) * 2015-11-13 2021-01-01 卫材R&D管理有限公司 吡喃并二吡啶化合物
EA201892666A1 (ru) * 2016-05-25 2019-08-30 Байер Фарма Акциенгезельшафт 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды
CN116531380B (zh) 2017-02-09 2025-11-07 拜耳股份公司 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺
MX2019012380A (es) 2017-05-09 2020-01-23 Eisai R&D Man Co Ltd Cristales de compuesto piranodipiridinico.
US11459312B2 (en) 2017-11-21 2022-10-04 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
EP3713931B1 (en) 2017-11-21 2025-03-05 Deutsches Krebsforschungszentrum 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
WO2019236625A1 (en) * 2018-06-04 2019-12-12 Ohio State Innovation Foundation Eaat2 activators and methods of using thereof
CA3105681A1 (en) * 2018-07-19 2020-01-23 Sumitomo Dainippon Pharma Co., Ltd. Pyridazinone derivative
BR112022013393A2 (pt) * 2020-01-06 2022-09-13 Australian Conveyor Components Pty Ltd Aparelho de limpeza de correia transportadora

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3014034A (en) * 1959-01-22 1961-12-19 Ciba Pharm Prod Inc 1, 3-diaryl, 5-amino-pyridazinones
US3018034A (en) * 1959-11-17 1962-01-23 Gen Applied Science Lab Inc Propulsion device for vertical takeoff aircraft
IL29949A (en) * 1967-05-19 1971-08-25 Seperic Diphenyl-pyridazones and process for preparing same
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69131268T2 (de) * 1990-09-21 1999-12-30 Rohm And Haas Co., Philadelphia Dihydropyridazinone und Pyridazinone als Fungizide
GB9206266D0 (en) * 1992-03-23 1992-05-06 Merck Sharp & Dohme Therapeutic agents
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
AU691673B2 (en) * 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
IL123340A0 (en) * 1997-02-20 1998-09-24 Sumitomo Chemical Co Pyridazin-3-one derivatives and their use
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000119257A (ja) * 1998-08-14 2000-04-25 Nippon Nohyaku Co Ltd ピリダジノン誘導体
KR100657189B1 (ko) * 1998-08-14 2006-12-14 니혼노야쿠가부시키가이샤 피리다지논 유도체 및 이를 함유하는 의약 조성물
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
KR100344790B1 (ko) * 1999-10-07 2002-07-19 엘지전자주식회사 마이크로 기계구조를 이용한 주파수 가변 초고주파 필터

Also Published As

Publication number Publication date
HUP0302508A2 (hu) 2003-12-29
JP2009007356A (ja) 2009-01-15
CA2422589C (en) 2011-08-09
AU9022901A (en) 2002-03-26
DE60137948D1 (de) 2009-04-23
HU228961B1 (en) 2013-07-29
US20060189622A1 (en) 2006-08-24
NO327813B1 (no) 2009-09-28
EP1319659B1 (en) 2009-03-11
CN100473647C (zh) 2009-04-01
NO20031232D0 (no) 2003-03-17
ATE425148T1 (de) 2009-03-15
EP1319659A4 (en) 2005-08-10
TWI262915B (en) 2006-10-01
NZ524745A (en) 2006-01-27
CA2742411A1 (en) 2002-03-21
HUP0302508A3 (en) 2007-03-28
CA2422589A1 (en) 2003-03-17
JPWO2002022587A1 (ja) 2004-01-22
IL154709A0 (en) 2003-10-31
US20030225081A1 (en) 2003-12-04
MXPA03002324A (es) 2003-06-06
WO2002022587A1 (en) 2002-03-21
AU2001290229B2 (en) 2006-12-07
EP1319659A1 (en) 2003-06-18
IL154709A (en) 2007-09-20
JP4906790B2 (ja) 2012-03-28
CN1458924A (zh) 2003-11-26
KR20030030007A (ko) 2003-04-16
JP4233868B2 (ja) 2009-03-04
KR100770327B1 (ko) 2007-10-25

Similar Documents

Publication Publication Date Title
NO20031232D0 (no) Pyridazinoner og triazinoner og medisinsk anvendelse derav
DE60221098D1 (de) Kondensierte heterocyclische derivate
DE60227794D1 (de) Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
MXPA03001136A (es) Compuesto de 2-aminopiridina y uso medico del mismo.
ATE449763T1 (de) 1h-indazolverbindungen die jnk hemmen
DE69211841D1 (de) Verbindungen mit herbiziden,acarizider und insektizider wirkung
ID25649A (id) Turunan-turunan sikloalkena, produksi serta penggunaannya
ATE425983T1 (de) Siloxy substituierte metallocenkatalysatoren
DK1221444T3 (da) Kondenserede imidazolforbindelser og lægemidler mod diabetes mellitus
CY1115302T1 (el) Ενωση οξαζολιου και φαρμακευτικη συνθεση
ATE438624T1 (de) 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
DE60026155D1 (de) Einige alkylendiamin-substituierte heterocyclen
CY1108367T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
DK0691967T3 (da) Nitrogenholdige kondenserede heterocykliske forbindelser
ATE503746T1 (de) Neue imidazolidinderivate
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
NO20070089L (no) DPP-IV inhibitorer
ATE222588T1 (de) Ein 1-methylcarbapenem-derivat
DE60107836D1 (de) Triazolderivate mit amidbindungen
DE50114053D1 (de) Verwendung von S-Ä2,3-Bispalmitoyloxy-(2RS)-propylÜcysteinyl-GNNDESNISFKEK (MALP-2)
ATE271051T1 (de) Heilmittel/vorbeugemittel für erkrankungen der atemwege
TH82581B (th) สารสำหรับป้องกันหรือรักษาโรคเส้นประสาท

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees